CHICAGO, January 12, 2026--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The ...
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
CHICAGO - Tempus AI, Inc. (NASDAQ:TEM), a $10 billion healthcare technology company showing impressive revenue growth of 43% over the past year, announced Tuesday the expansion of its Tempus Next care ...
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
Tempus AI TEM sits at the intersection of diagnostics, data and artificial intelligence. The company is building a precision medicine platform designed to help physicians, researchers and drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results